Cholera pp 285-327 | Cite as

Immunity and Vaccine Development

  • Myron M. Levine
  • Nathaniel F. Pierce
Part of the Current Topics in Infectious Disease book series (CTID)

Abstract

Public health authorities would like to have at their disposal a safe, practical, inexpensive, and highly effective vaccine to provide long-term protection against cholera. The Diarrheal Diseases Control Programme of the World Health Organization has targeted the development of an improved vaccine against cholera as a high priority.1 Such a vaccine to combat cholera is not yet in the public health armamentarium but, as shown in this chapter, several promising candidates are on the horizon.

Keywords

Cholera Toxin Oral Vaccine Oral Immunization Vibrio Cholerae Combination Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Diarrhoeal Diseases Control Programme: Biomedical and Epidemiological Research Priorities of Global Scientific Working Groups. WHO/CDD/86.8 Rev.l (1987). Geneva, World Health Organization, 1987.Google Scholar
  2. 2.
    Goodgame RW, Greenough WB: Cholera in Africa: a message for the West. Ann Inter Med 82: 101–106, 1975.CrossRefGoogle Scholar
  3. 3.
    Umoh JU, Adesiyun AA, Adekeye JO, et al: Epidemiological features of an outbreak of gastroenteritis/cholera in Katsina, Northern Nigeria. J Hyg (Camb.) 91: 101–111, 1983.CrossRefGoogle Scholar
  4. 4.
    Ferran J: Nota sobre la profilixas del colera por medio de inyecciones hipodermicas de cultivo puro del bacilo virgula? Siglo Med 32: 480, 1885.Google Scholar
  5. 5.
    Bornside GH: Jaime Ferran and preventive inoculation against cholera. Bull Hist Med 55: 516–532, 1981.PubMedGoogle Scholar
  6. 6.
    Koch R: Der zweite Bericht der deutschen Cholera-Commission. Dtsch Med Wochschr 9: 743–744, 1883.Google Scholar
  7. 7.
    Bornside: GH: Waldemar Haffkine’s cholera vaccines and the Ferran-Haffkine priority dispute. J Hist Med All Sci 37: 399–422, 1982.CrossRefGoogle Scholar
  8. 8.
    Kolle W: Die aktive Immunisierung des Menschen gegen Cholera nach Haffkine’s Verfahren in Indien. Zbl Bakt I Abt Orig 19: 217–221, 1896.Google Scholar
  9. 9.
    Voges O: Die Cholera-Immunitat. Zbl Bakt I Abt Orig 19: 325–241, 395.-400, 444-470, 1896.Google Scholar
  10. 10.
    Haffkine WM: Les vaccinations anticholeriques aux Indes. Bull Inst Pasteur 4: 697–705, 737.-747, 1906.Google Scholar
  11. 11.
    Haffkine, WM: Protective inoculation against cholera, Calcutta. C R Soc Biol (Paris) 4: 635–671, 1985.Google Scholar
  12. 12.
    Cvjetanovic B: Contribution of Haffkine to the concept and practice of controlled field trials. Fortschr Arzneimittforsch 19: 481–489, 1975.Google Scholar
  13. 13.
    Kolle W: Zur aktiven Immunisierung des Menschen gegen Cholera. Zbl Bakt I Abt Orig 19: 97–104, 1896.Google Scholar
  14. 14.
    Murata N: Uber die Schutzimpfung gegen Cholera. Zbl Bakt I Abt Orig 35: 605–608, 1904.Google Scholar
  15. 15.
    Sawtschenko J, Sabolotny DK: Versuch einer Immunisation des menschen gegen Cholera. Zbl allg Path Path Anat 4: 625–636, 1893.Google Scholar
  16. 16.
    Russell AJH: Besredka’s cholera bilivaccin versus anti-cholera vaccine: a comparative field test, in: Transactions of the Seventh Congress of the Far Eastern Association of Tropical Medicine, 1927, Calcutta, Vol 1. p 253.Google Scholar
  17. 17.
    Russell AJH: Le bilivaccin anticholerique et le vaccin anticholerique ordinaire. Essai de comparaison pratique, in: Graham JD, Recherhes sur le choiera et la vaccination anticholerique dans l’Inde Brittanique. Bull Off Int Hyg Publ 20: 703–709, 1928.Google Scholar
  18. 18.
    Russell AJH: Cholera in India, in: Transactions of the Ninth Congress of the Far Eastern Association of Tropical Medicine, 1934, Nanking, Vol 1. p 398.Google Scholar
  19. 19.
    Sarramon: Sur l’emploi du vaccin anticholerique psr voie buccale. Bull Soc Med-Chir Indochine 8: 180–183, 1930.Google Scholar
  20. 20.
    Cash RA, Music SI, Libonati JP, et al: Response of man to infection with Vibrio cholerae. Protection from illness afforded by previous disease and vaccine. J Infect Dis 130: 325–333, 1974.PubMedCrossRefGoogle Scholar
  21. 21.
    Levine MM, Nalin DR, Craig JP, et al: Immunity to cholera in man: relative role of antibacterial versus antitoxic immunity. Trans Roy Soc Trop Med Hyg 73: 3–9, 1979.PubMedCrossRefGoogle Scholar
  22. 22.
    Levine MM: Immunity to cholera as evaluated in volunteers, in Ouchterlony O, Holmgren J (ed): Cholera and Related Diarrheas. Basel, S. Karger, 1980, pp 195-203.Google Scholar
  23. 23.
    Levine MM, Black RE, Clements ML, et al: Volunteer studies in development of vaccines against cholera and enterotoxigenic Escherichia coli: a review, in Holme T, Holmgren J, Merson M, Mollby R (eds): Acute Enteric Infections in Children: New Prospects for Treatment and Prevention. Amsterdam, Elsevier/North Holland, 1981.Google Scholar
  24. 24.
    Levine MM, Black RE, Clements ML, et al: The quality and duration of infection-derived immunity to cholera. J Infect Dis 143: 818–820, 1981.PubMedCrossRefGoogle Scholar
  25. 25.
    Levine, MM, Kaper JB, Black RE, et al: New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 47: 510–550, 1983.PubMedGoogle Scholar
  26. 26.
    Shedlofsky S, Freter R: Synergism between ecologic and immunologic control mechanism. J Infect Dis 129: 296–303, 1974.PubMedCrossRefGoogle Scholar
  27. 27.
    Woodward WE: Cholera reinfection in man. J Infect Dis 123: 61–66, 1971.PubMedCrossRefGoogle Scholar
  28. 28.
    Glass RI, Becker S, Huq MI, et al: Endemic cholera in rural Bangladesh, 1966–1980. Am J Epidemiol 116: 959–970, 1982.PubMedGoogle Scholar
  29. 29.
    Glass RI, Svennerholm A-M, Stoll B, et al: Protection against cholera in breast-fed children by antibodies in breast milk. N Eng J Med 308: 1389–1392, 1983.CrossRefGoogle Scholar
  30. 30.
    Glass RI, Svennerholm A-M, Khan RN, et al: Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151: 236–242, 1985.PubMedCrossRefGoogle Scholar
  31. 31.
    Benenson AS: Review of experience with whole-cell and somatic antigen cholera vaccines, in: Symposium on Cholera, Sapporo, 1976. US-Japan Cooperative Medical Science Program, National Institute of Health, Tokyo, 1977, pp 228–252.Google Scholar
  32. 32.
    FeeleyJC, Gangarosa EJ: Field trials of cholera vaccine, in Cholera and Related Diarrheas, 43rd Nobel Symposium, Stockholm, 1978. Basel, Karger, 1980, pp 204-210.Google Scholar
  33. 33.
    Joo I: Cholera vacines, in Barua D, Burrows W (eds): Cholera. Philadelphia, WB Saunders, 1974, pp 333–335.Google Scholar
  34. 34.
    Oseasohn RO, Benenson AS, Fahimuddin Md: Field trial of cholera vaccine in rural East Pakistan. Lancet i: 450–453, 1965.CrossRefGoogle Scholar
  35. 35.
    Benenson AS, Mosley WH, Fahimuddin M, et al: Cholera vaccine field trials in East Pakistan. 2. Effectiveness in the field. Bull WHO 38: 359–372, 1968.PubMedGoogle Scholar
  36. 36.
    Mosley WH, McCormack WM, Ahmed A, et al: Report of the 1966-67 cholera field trial in rural East Pakistan. 2. Results of the serological surveys in the study population—the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull WHO 40: 187–197, 1969.PubMedGoogle Scholar
  37. 37.
    Mosley WH: The role of immunity in cholera. A review of epidemiological and serological studies. Texas Rep Biol Med 27 (l): 227–244, 1969.Google Scholar
  38. 38.
    Mosley WH, McCormack WM, Ahmed A, et al: Report of the 1966–67 cholera vaccine field trial in rural East Pakistan. 1. Study design and results of the first year of observation. Bull WHO 40: 177–185, 1969.PubMedGoogle Scholar
  39. 39.
    Mosley WH, Woodward WE, Aziz KMS, et al: The 1968-1969 cholera vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J Infect Dis 121:S1–S9, 1970.CrossRefGoogle Scholar
  40. 40.
    Mosley, WH, Aziz KMS, Mizanur Rahman ASM, et al: Report of the 1966–67 cholera vaccine trial in rural East Pakistan. Bull WHO 47: 229–238, 1972.PubMedGoogle Scholar
  41. 41.
    Mosley WH, Aziz KMS, Mizanur Rahman ASM, et al: Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh—three years of observation. Bull WHO 49: 381–387, 1973.PubMedGoogle Scholar
  42. 42.
    Philippines Cholera Committee: A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Bull WHO 32: 603–625, 1965.Google Scholar
  43. 43.
    Azurin JC, Cruz A, Pesigan TP, et al: A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Bull WHO 37: 703–727, 1967.PubMedGoogle Scholar
  44. 44.
    Philippines Cholera Committee: A controlled field trial of the effectiveness of various doses of cholera El Tor Vaccine in the Philippines. Bull WHO 38: 917–923, 1968.Google Scholar
  45. 45.
    Das Gupta A, Sinha R, Shrivastava DL, et al: Controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in Calcutta. Bull WHO 37: 371–385, 1967.PubMedGoogle Scholar
  46. 46.
    Pal SC, Deb BC, Sen Gupta PG, et al: A controlled field trial of an aluminum phosphate-adsorbed cholera vaccine in Calcutta. Bull WHO 58: 741–745, 1980.PubMedGoogle Scholar
  47. 47.
    Saroso JS, Bahrawi W, Witjaksono H, et al: A controlled field trial of plain and aluminum hydroxide-adsorbed cholera vaccines in Surabaya, Indonesia, during 1973–75. Bull WHO 56: 619–627, 1978.PubMedGoogle Scholar
  48. 48.
    Clemens JD, Sack DA, Harris JR, et al: Field trial of oral cholera vaccines in Bangladesh. Lancet ii: 124–127, 1986.CrossRefGoogle Scholar
  49. 49.
    Freter R: Studies on the mechanism of action of intestinal antibody in experimental cholera. Texas Rep Exp Biol Med 27: 299–316, 1969.Google Scholar
  50. 50.
    Neoh SH, Rowley D: Protection of infant mice against cholera by antibodies to three Vibrio cholerae antigens. J Infect Dis 126: 41–47, 1972.PubMedCrossRefGoogle Scholar
  51. 51.
    Fubara ES, Freter R: Protection against enteric infection by secretory antibodies. J Immunol 111: 395–403, 1973.PubMedGoogle Scholar
  52. 52.
    Bellamy JEC, Knop EJ, Steele EJ, et al: Antibody cross-linking as a factor in immunity to cholera in infant mice. J Infect Dis 132: 181–188, 1975.PubMedCrossRefGoogle Scholar
  53. 53.
    Steele EJ, Chaicumpa W, Rowley D: Further evidence for cross-linking as a protective factor in experimental cholera: properties of antibody fragments. J Infect Dis 132: 175–180, 1975.PubMedCrossRefGoogle Scholar
  54. 54.
    Guentzel MN, Field LH, Eubanks ER, et al: Use of flourescent antibody in studies of immunity to cholera in infant mice. Infect Immun 15: 539–548, 1977.PubMedGoogle Scholar
  55. 55.
    Eubanks ER, Guentzel MN, Berry LJ: Evaluation of surface components of Vibrio cholerae as protective immunogens. Infect Immun 15: 533–538, 1977.PubMedGoogle Scholar
  56. 56.
    Yancey RJ, Willis DL, Berry LJ: Flagella-induced immunity against experimental cholera in adult rabbits. Infect Immun 25: 220–228, 1979.PubMedGoogle Scholar
  57. 57.
    Hranitsky KW, Mulholland A, Larson AD, et al: Characterization of a flagellar sheath protein of Vibrio cholerae. Infect Immun 27: 597–603, 1980.Google Scholar
  58. 58.
    Chaicumpa W, Atthasisishtha N: Study of intestinal immunity against V. cholerae: role of antibody to V. cholerae haemagglutinin in intestinal immunity. SE Asian J Trop Med Publ Hlth 8: 13–18, 1977.Google Scholar
  59. 59.
    Fujita K, Finkelstein RA: Antitoxic immunity in experimental cholera: comparison of immunity induced perorally and parenterally in mice. J Infect Dis 125: 647–655, 1972.PubMedCrossRefGoogle Scholar
  60. 60.
    Holmgren J, Svennerholm A-M, Ouchterlony O, et al: Antitoxic immunity in experimental cholera: protection and serum and local antibody responses in rabbits after enteric and parenteral immunization. Infect Immun 12: 463–470, 1975.Google Scholar
  61. 61.
    Pierce, NF, Sack RB, Sircar BK: Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral toxoid administration to dogs. J Infect Dis 135: 888–896, 1977.PubMedCrossRefGoogle Scholar
  62. 62.
    Pierce NF, Reynolds HY: Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization. J Immunol 113: 1017–1023, 1974.PubMedGoogle Scholar
  63. 63.
    Pierce NF, Cray WC Jr, Sircar BK: Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera. Infect Immun 21: 185–193, 1978.PubMedGoogle Scholar
  64. 64.
    Lange S, Hansson H-A, Molin S-O, et al: Local cholera immunity in mice: intestinal antitoxin-containing cells and their correlation with protective immunity. Infect Immun 23: 743–750, 1979.PubMedGoogle Scholar
  65. 65.
    Svennerholm A-M, Lange S, Holmgren J: Correlation between intestinal synthesis of specific immunoglobulin A and protection against experimental cholera in mice. Infect Immun 21: 1–6, 1978.PubMedGoogle Scholar
  66. 66.
    Pierce NF, Cray WC Jr, Engel PF: Antitoxic immunity to cholera in dogs immunized orally with cholera toxin. Infect Immun 27: 632–637, 1980.PubMedGoogle Scholar
  67. 67.
    Pierce NF, Cray WC Jr, Sacci JB Jr: Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms. Infect Immun 37: 687–694, 1982.PubMedGoogle Scholar
  68. 68.
    Peterson JW: Protection against experimental cholera by oral or parenteral immunization. Infect Immun 26: 594–598, 1979.PubMedGoogle Scholar
  69. 69.
    Pierce, NF, Cray WC Jr, Sacci JB Jr, et al: Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera. Infect Immun 40: 1112–1118, 1983.PubMedGoogle Scholar
  70. 70.
    Svennerholm A-M, Holmgren J: Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun 13: 735–740, 1976.PubMedGoogle Scholar
  71. 71.
    Holmgren J, Svennerholm A-M: Mechanisms of disease and immunity in cholera: a review. J Infect Dis 136:S105–S112, 1977.PubMedCrossRefGoogle Scholar
  72. 72.
    Peterson JW: Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine. Infect Immun 26: 528–533, 1979.PubMedGoogle Scholar
  73. 73.
    Resnick IG, Ford CW, Shackleford GM, et al: Improved protection against cholera in adult rabbits with a combined flagellar-toxoid vaccine. Infect Immun 30: 375–380, 1980.PubMedGoogle Scholar
  74. 74.
    Chaicumpa W, Boonthum A, Kalumbaheti T, et al. Cell-bound haemagglutinin (CHA) of V. cholerae 01 as protective antigen. SE Asian J Trop Med Publ Hlth 15: 407–413, 1984.Google Scholar
  75. 75.
    Levine MM, Kaper JB, Herrington D, et al: Deletion mutants of Vibrio cholerae 01 prepared by recombinant techniques: insights on pathogenesis and immunity. Infect Immun 1988: in press.Google Scholar
  76. 76.
    Black RE, Levine MM, Clements ML, et al: Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun 55: 1116–1120, 1987.PubMedGoogle Scholar
  77. 77.
    Kaper JB, Lockman H, Baldini M, et al: Recombinant nontoxigenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature 308: 655–658, 1984.PubMedCrossRefGoogle Scholar
  78. 78.
    Curlin G, Levine R, Aziz KMS, et al: Field trial of cholera toxoid, in: Proceedings of the 11th Joint Conference on Cholera. U.S.-Japan Cooperative Medical Science Program, 1975, pp 314-329.Google Scholar
  79. 79.
    Noriki H: Evaluation of toxic field trial on the Philippines, in Fukumi H, Zinnaka Y (eds): Proceedings of the 12th Joint Conference on Cholera, U.S.-Japan Cooperative Medical Science Program. Sapporo. Fuji, Tokyo, 1976, pp 302-310.Google Scholar
  80. 80.
    Clemens JD, Harris JR, Sack DA, et al: Field trial of oral cholera vaccines in Bangladesh: results of one year follow-up. J Infect Dis 158: 60–69, 1988.PubMedCrossRefGoogle Scholar
  81. 81.
    Clemens JD, Sack DA, Harris Jr, et al: Field trial of oral cholera vaccines in Bangladesh: results from three year follow-up. Lancet 335: 270–273, 1990.PubMedCrossRefGoogle Scholar
  82. 82.
    Clemens JD, Sack DA, Harris JR, et al: Cross-protection by B subunit-whole cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158: 372–377, 1988.PubMedCrossRefGoogle Scholar
  83. 83.
    Neoh SE, Rowley D: The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J Infect Dis 121: 505–513, 1970.PubMedCrossRefGoogle Scholar
  84. 84.
    Kaur J, Burrows W: Immunity to cholera: relation of fraction II of type 2 cholera toxin to vibriocidal. J Bacteriol 98: 467-474.Google Scholar
  85. 85.
    Attridge SR, Rowley D: Prophylactic significance of the nonpolysaccharide antigens of Vibrio cholerae. J Infect Dis 148: 931–939, 1983.PubMedCrossRefGoogle Scholar
  86. 86.
    Ahmad A, Bhattacharjee AK, Mosley WH: Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and normal residents of the endemic and non-endemic cholera areas. J Immunol 105: 431–441, 1970.Google Scholar
  87. 87.
    Merritt CB, Sack RB: Sensitivity of agglutinating and vibriocidal antibodies to 2-mercaptoethanol in human cholera. J Infect Dis 121:S25-S30.Google Scholar
  88. 88.
    Majumdar AS, Ghose AC: Evaluation of the biological properties of different classes of human antibodies in relation to cholera. Infect Immun 32: 9–14, 1981.PubMedGoogle Scholar
  89. 89.
    Clements ML, Levine MM, Young CR, Black RE, Lim Y-L, Robins-Browne RM: Magnitude, kinetics and duration of vibriocidal antibody response in North Americans after ingestion of Vibrio cholerae. J Infect Dis 145: 465–473, 1982.PubMedCrossRefGoogle Scholar
  90. 90.
    Tomasi TB: The Immune System of Secretions. Englewood Cliffs, NJ, Prentice-Hall, 1976.Google Scholar
  91. 91.
    Waldman RH, Bencic Z, Sakazaki R, et al: Cholera immunology. II. Serum and intestinal secretion antibody response after naturally-occurring cholera. J Infect Dis 126: 401–407, 1972.PubMedCrossRefGoogle Scholar
  92. 92.
    Champsur H, Iscaki S, Bernard, et al: Induction of Vibrio cholerae specific biliary antibodies after oral immunization with a cholera cell wall fraction. Lancet i: 1276–1277, 1985.CrossRefGoogle Scholar
  93. 93.
    Estavoyer JM, Panouse-Perrin J, Dodin A, et al: La maladie cholerique: etude serologiques d’un cas. Bull Soc Path Ex 75: 242–247, 1982.Google Scholar
  94. 94.
    Chaicumpa W, Rowley D: Experimental cholera in infant mice: protective effects of antibody. J Infect Dis 125: 480–485, 1972.PubMedCrossRefGoogle Scholar
  95. 95.
    Freter R, Jones GW: Adhesive properties of Vibrio cholerae: nature of the interaction with intact mucosal surfaces. Infect Immun 14: 246–256, 1976.PubMedGoogle Scholar
  96. 96.
    Chitnis DS, Sharma KD, Kamat RS: Role of somatic antigen of Vibrio cholerae in adhesion to intestinal mucosa. J Med Microbiol 5: 53–61, 1982.CrossRefGoogle Scholar
  97. 97.
    Benenson AS, Saad A, Mosley WH, et al: Serological studies in cholera. 3. Serum toxin neutralization—Rise in titre in response to infection with Vibrio cholerae, and the level in the “normal” population of East Pakistan. Bull WHO 38: 287–295, 1968.PubMedGoogle Scholar
  98. 98.
    Levine MM, Young CR, Hughes TP, et al: Duration of serum antitoxin response following Vibrio cholerae infection in North Americans: relevance for seroepidemiology. Am J Epidemiol 114: 348–354, 1981.PubMedGoogle Scholar
  99. 99.
    Levine MM, Young CR, Black RE, et al: Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol 21: 174–179, 1985.PubMedGoogle Scholar
  100. 100.
    Svennerholm A-M, Jertborn M, Gothefors L, et al: Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit whole cell vaccine. J Infect Dis 149: 884–893, 1984.PubMedCrossRefGoogle Scholar
  101. 101.
    Taylor R, Miller VL, Furlong DB, et al: Use of phoA gene fusions to identity a pilus colonization factor coordinately regulated with cholera toxin. Proc Nat Acad Sci USA 84: 2833–2837, 1987.PubMedCrossRefGoogle Scholar
  102. 102.
    Miller VL, Mekalanos JJ: Synthesis of cholera toxin is positively regulated at the transcriptional level by toxR. Proc Nat Acad Sci USA 81: 3471–3475, 1984.PubMedCrossRefGoogle Scholar
  103. 103.
    Hall R, Vial PA, Kaper JB, et al: Morphological studies on fimbriae expressed by Vibrio cholerae 01. Microbial Path 4: 257–265, 1988.CrossRefGoogle Scholar
  104. 104.
    Herrington DA, Hall RH, Losonsky G, et al: Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 168: 1487–1492, 1988.PubMedCrossRefGoogle Scholar
  105. 105.
    Taylor RK, Shaw C, Peterson K, et al: Safe, live Vibrio cholerae vaccines? Vaccines 6: 151–154, 1988.CrossRefGoogle Scholar
  106. 106.
    Mestecky J, McGhee JR: Immunoglobulin A (IgA) molecular and cellular interaction involved in IgA biosynthesis and immune response. Adv Immunol 40: 153–245, 1987.PubMedCrossRefGoogle Scholar
  107. 107.
    Pierce NF, Gowans: Cellular kinetics of the intestinal immune response to cholera toxoid in rats. J Exp Med 142: 1550–1563, 1975.PubMedCrossRefGoogle Scholar
  108. 108.
    Weisz-Carrington P, Roux ME, Mc Williams M, et al: Organ and isotype distribution of plasma cells producing specific antibody after oral immunization: evidence for a generalized secretory immune system. J Immunol 123: 1705-1708.Google Scholar
  109. 109.
    Strober W, Hanson LA, Sell KW: Recent Advances in Mucosal Immunity. New York, Raven Press, 1982.Google Scholar
  110. 110.
    Jertborn M, Svennerholm A-M, Holmgren J: Gut mucosal, salivary and serum antitoxic and antibacterial antibody responses in Swedes after oral immunization with B subunit-whole cell cholera vaccine. Int Archs Allergy Appl Immun 75: 38–43, 1984.CrossRefGoogle Scholar
  111. 111.
    Jertborn M, Svennerholm A-M, Holmgren J: Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol 24: 203–209, 1986.PubMedGoogle Scholar
  112. 112.
    Majumdar AS, Dutta P, Dutta D, et al: Antibacterial and antitoxin responses in the serum and milk of cholera patients. Infect Immun 32: 1–8, 1981.PubMedGoogle Scholar
  113. 113.
    Lange S, Vygren H, Svennerholm A-M, et al: Antitoxic cholera immunity in mice. Influence of antigen deposition on antitoxin-containing cells and protective immunity in different parts of intestine. Infect Immun 28: 17–23, 1980.PubMedGoogle Scholar
  114. 114.
    Pierce NF: The role of antigen form and function in the primary and secondary intestinal immune responses to cholera toxin and toxoid in rats. J Exp Med 148: 195–206, 1978.PubMedCrossRefGoogle Scholar
  115. 115.
    Lycke N, Holmgren J: Intestinal mucosal memory and presence of memory cells in lamina proporia and Peyer’s patches in mice 2 years after oral immunization with cholera toxin. Scand J Immunol 23: 611–616, 1986.PubMedCrossRefGoogle Scholar
  116. 116.
    Svennerholm A-M, Gothefors L, Sack DA, et al: Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes. Bull WHO 62: 909–918, 1984.PubMedGoogle Scholar
  117. 117.
    Svennerholm A-M, Hanson LA, Holmgren J, et al: Different secretory immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women. Infect Immun 30: 427–430, 1980.PubMedGoogle Scholar
  118. 118.
    Levine MM, Black RE, Clements ML, et al: Prevention of enterotoxigenic Escherichia coli diarrheal infection by vaccines that stimulate anti-adhesion (anti-pili) immunity, in Boedeker EC (ed): Attachment of Organisms to the Gut Mucosa, Boca Raton, CRC Press, 1984, pp 223–244.Google Scholar
  119. 119.
    Yardley JM, Keren DF, Hamilton SR, et al: Local (immunoglobulin A) immune responses by the intestine to cholera toxin and its partial suppression by combined systemic and intra-intestinal immunization. Infect Immun 19: 589–597, 1978.PubMedGoogle Scholar
  120. 120.
    Pierce NF, Koster FT: Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats. J Immunol 124: 307–311, 1980.PubMedGoogle Scholar
  121. 121.
    Philippines Cholera Committee: A controlled field trial of the effectiveness of monovalent classical and El Tor cholera vaccines in the Philippines. Bull WHO 49: 13–19, 1973.Google Scholar
  122. 122.
    Northrup RS, Chisari FV: Response of monkeys to immunization with cholera toxoid, toxin, and vaccine: reversion of cholera toxoid. J Infect Dis 125: 471–479, 1972.PubMedCrossRefGoogle Scholar
  123. 123.
    Black RE, Yunus Md, Eusof A, et al: Report and immunogenicity of Wellcome cholera toxoids in Bangladeshi volunteers. International Centre for Diarrhoeal Disease Research, Bangladesh, Scientific Report No. 29, Dacca, 1979.Google Scholar
  124. 124.
    Merson MN, Black RE, Sack DA, et al: Maternal cholera immunisation and secretory IgA in breast milk. Lancet i: 931–932, 1980.CrossRefGoogle Scholar
  125. 125.
    Ohtomo N: Safety and potency tests of cholera toxoid lot 11 in animals and volunteers, in Fukumi H, Zinnaka Y (eds): Proceedings of the 12th Joint Conference on Cholera. US-Japan Cooperative Medical Science Program, Sapporo, Fuji, Tokyo, 1976, pp 286-296.Google Scholar
  126. 126.
    Rappaport RS, Pierzchala WA, Bonde G, et al: Development of a purified cholera toxin. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen. Infect Immun 14: 687–693, 1976.PubMedGoogle Scholar
  127. 127.
    Finkelstein RA, Fujita K, Lospallutto JJ: Procholeragenoid: an aggregated intermediate in the formation of choleragenoid. J Immunol 107: 1043–1051, 1971.PubMedGoogle Scholar
  128. 128.
    Germanier R, Furer E, Varallyay S, et al: Preparation of a purified antigenic cholera toxoid. Infect Immun 13: 1692–1698, 1976.PubMedGoogle Scholar
  129. 129.
    Germanier R, Furer E, Varallyay S, et al: Antigenicity of cholera toxoid in humans. J Infect Dis 135: 512–516, 1977.PubMedCrossRefGoogle Scholar
  130. 130.
    Holmgrem J, Svennerholm A-M, Lonnroth I, et al: Development of an improved cholera vaccine based on subunit toxoid. Nature 269;602–604, 1977.CrossRefGoogle Scholar
  131. 131.
    Holmgren J: Actions of cholera toxin and the prevention and treatment of cholera. Nature 292: 413–417, 1981.PubMedCrossRefGoogle Scholar
  132. 132.
    Svennerholm A-M, Sack DA, Holmgren J, et al: Intestinal antibody responses after immunisation with cholera B subunit. Lancet i: 305–308, 1982.CrossRefGoogle Scholar
  133. 133.
    Freter R: Detection of coproantibody and its formation after parenteral and oral immunization of human volunteers. J Infect Dis 111: 37–48, 1962.CrossRefGoogle Scholar
  134. 134.
    Freter R, Gangarosa EJ: Oral immunization and production of coproantibody in human volunteers. J Immunol 91: 724–729, 1963.PubMedGoogle Scholar
  135. 135.
    Ganguly R, Clem LW, Benck Z, et al: Antibody response in the intestinal secretions of volunteers immunized with various cholera vaccines. Bull WHO 52: 323–330, 1975.PubMedGoogle Scholar
  136. 136.
    Denchev V, Jeleva M, Duncheve St: Human immunization with killed cholera vaccine. Acta Microbiol Acad Sci Hung 21: 209–212, 1974.PubMedGoogle Scholar
  137. 137.
    Oberdoerster F, Thilo W: A new inactivated oral cholera vaccine. Acta Microbiol Acad Sci Hung 21: 213–215, 1974.PubMedGoogle Scholar
  138. 138.
    Clemens JD, Jertborn M, Sack DA, et al: Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole cell cholera vaccine. J Infect Dis 154: 175–178, 1986.PubMedCrossRefGoogle Scholar
  139. 139.
    Dodin A, Plawecki M: Étude sur l’animal de fractions antigeniques radio-actives isoless de V. cholerae. I. La fraction de Ch 1 + 2. Bull Soc Path Ex 71: 22–33, 1977.Google Scholar
  140. 140.
    Dodin A: Les antigenes vaccinants. Bordeaux Medical 2: 299–301, 1979.Google Scholar
  141. 141.
    Dodin A: Un vaccin oral contre le cholera. A Recherche 110: 468–469, 1980.Google Scholar
  142. 142.
    Gateff C, Dodin A, Wiart J: Comparaison des reactions serologiques induites par un vaccine anticholerique classique et une fraction vaccinante purifiée associés ou non au vaccin anti-amaril. Ann Microbiol 126A:231–246, 1975.Google Scholar
  143. 143.
    Dodin A, Masengo B, Loucq C: Resultats controles du vaccin anticholerique oral de l’Institut Pasteur au cours de l’épidemie du Shaba-Zaire en 1983. C.R. Acad Sci Paris serie III 299: 205–207, 1984.Google Scholar
  144. 144.
    Levine MM, Hughes, TP, Young CR, et al: Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally. Infect Immun 21: 158–162, 1978.PubMedGoogle Scholar
  145. 145.
    Sanyal S, Mukerjee S: Live oral cholera vaccine: report of a trial on human volunteer subjects. Bull WHO 40: 503–511, 1969.PubMedGoogle Scholar
  146. 146.
    Cash RA, Music SI, Libonati JP, et al: Live oral cholera vaccine: evaluation of the clinical effectiveness of two strains in humans. Infect Immun 10: 762–764, 1974.PubMedGoogle Scholar
  147. 147.
    Levine MM, Black RE, Clements ML, et al: The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup 01 biotype El Tor isolated from sewage water in Brazil. J Infect Dis 145: 296–299, 1982.PubMedCrossRefGoogle Scholar
  148. 148.
    Finkelstein RA, Vasil ML, Holmes RD: Studies on toxigenesis in Vibrio cholerae. l. Isolation of mutants with altered toxigenicity. J Infect Dis 129: 117–123, 1974.PubMedCrossRefGoogle Scholar
  149. 149.
    Holmes RK, Vasil ML, Finkelstein RA: Studies on toxigenesis in Vibrio cholerae. III. Characterization of nontoxigenic mutants in vitro and in experimental animals. J Clin Invest 55: 551–560, 1975.PubMedCrossRefGoogle Scholar
  150. 150.
    Woodward WE, Gilman RH, Hornick RB, et al: Efficacy of a live oral cholera vaccine in human volunteers. Dev Biol Stand 33: 108–112, 1976.PubMedGoogle Scholar
  151. 151.
    Honda T, Finkelstein RA: Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin. Proc Natl Acad Sci USA 76: 2052–2056, 1979.PubMedCrossRefGoogle Scholar
  152. 152.
    Levine MM, Black RE, Clements ML, et al: Evaluation in man of attenuated Vibrio cholerae El Tor Ogawa strain Texas-Star SR as live oral vaccine. Infect Immun 43: 515–522, 1984.PubMedGoogle Scholar
  153. 153.
    Mekelanos JJ, Moseley SL, Murphy JR, et al: Isolation of enterotoxin structural gene deletion mutations in Vibrio cholerae induced by two mutagenic vibriophages. Proc Natl Acad Sci USA 79: 151–155, 1982.CrossRefGoogle Scholar
  154. 154.
    Manning PA, Heuzenroeder MW, Yeadon J, et al: Molecular cloning and expression in Escherichia coli K-12 of the O antigens of the Inaba and Ogawa serotypes of the Vibrio cholerae 01 lipolysaccharides and their potential for vaccine development. Infect Immun 53: 272–277, 1986.PubMedGoogle Scholar
  155. 155.
    Wahdan MH, Serie C, Germanier R, et al: A controlled field trial of live oral typhoid vaccine Ty21a. Bull WHO 58: 469–474, 1980.PubMedGoogle Scholar
  156. 156.
    Levine MM, Ferreccio C, Black RE, et al: Large-scale field trial of Ty21a typhoid vaccine in enteric-coated capsule formulation. Lancet i: 1049–1052, 1987.CrossRefGoogle Scholar
  157. 157.
    Levine MM, Herrington D, Murphy J, et al: Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541 Ty and 543 Ty, as live oral vaccines in human. J Clin Invest 79: 888–902, 1987.PubMedCrossRefGoogle Scholar
  158. 158.
    Kaper JB, Lockman H, Baldini MM, et al: Recombinant live oral cholera vaccine. Biotechnology 2: 345–349, 1984.CrossRefGoogle Scholar
  159. 159.
    Mekalanos JJ, Swartz DJ, Pearson GDN, et al: Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature 306: 551–557, 1983.PubMedCrossRefGoogle Scholar
  160. 160.
    Levine MM, Black RE, Clements ML, et al: Present status of cholera vaccines. Biochem Soc Trans 12: 200–202, 1984.PubMedGoogle Scholar
  161. 161.
    Levine MM, Kaper JB, Black RE, et al: Landmarks on the road toward a live oral attenuated cholera vaccine, in Takeda Y (ed): Vibrio cholerae and Cholera. Tokyo, KTK Scientific Publishers, 1988 pg 155–161.Google Scholar
  162. 162.
    Levine MM, Kaper JB, Herrington D, et al: Volunteer studies of deletion mutants of Vibrio cholerae 01 prepared by recombinant techniques. Infect Immun 56: 161–167, 1988.PubMedGoogle Scholar
  163. 163.
    Kaper JB, Levine MM, Lockman H, et al: Development and testing of recombinant live oral cholera vaccine, in: Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial and Viral Diseases. Cold Spring Harbor Laboratories, 1985, pp 107-111.Google Scholar
  164. 164.
    Glass RI, Holmgren J, Haley CE, et al: Predisposition for cholera of individuals with O blood group. Am J Epidemiol 121: 791–796, 1985.PubMedGoogle Scholar
  165. 165.
    Levine MM, Nalin DR, Renneis MB, et al: Genetic susceptibility to cholera. Ann Human Biol 6: 369–374, 1979.CrossRefGoogle Scholar
  166. 166.
    Ichinose Y, Yamomoto K, Nakasone N, et al: Enterotoxicity of El Tor-like hemolysin of non-01 Vibrio cholerae. Infect Immun 55: 1090-1093.Google Scholar
  167. 167.
    Madden JM, McCardell BA, Shah DB: Cytotoxin production by members of genus Vibrio. Lancet i: 1217–1218, 1984.CrossRefGoogle Scholar
  168. 168.
    Nishibuchi M, Seidler RJ, Rollins DM, et al: Vibrio factors cause rapid fluid accumulation in suckling mice. Appl Environ Microbiol 45: 228–231, 1983.PubMedGoogle Scholar
  169. 169.
    O’Brien AD, Chen ME, Holmes RK, et al: Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga-like) cytotoxin. Lancet i: 77–78, 1984.CrossRefGoogle Scholar
  170. 170.
    Sanyal SC, Neogi PKB, Alam K, et al: A new enterotoxin produced by Vibrio cholerae 01. J Diar Dis Res 2: 3–12, 1984.Google Scholar
  171. 171.
    Yamamoto K, Ichinose Y, Nakasone N, et al: Identity of hemolysins produced by Vibrio cholerae non-01 and V. cholerae 01, biotype El Tor. Infect Immun 51: 927–931, 1986.PubMedGoogle Scholar
  172. 172.
    Yamamoto K, Maliha A-O, Honda T, et al: Non-01 Vibrio cholerae hemolysin: purification, partial characterization, and immunological relatedness to El Tor hemolysin. Infect Immun 45: 192-196.Google Scholar
  173. 173.
    Richardson K, Michalski J, Kaper JB: Hemolysin production and cloning of two hemolysin determinants from classical Vibrio cholerae. Infect Immun 54: 415–420, 1986.PubMedGoogle Scholar
  174. 174.
    Levine MM, Kaper JB, Herrington D, et al: Safety, immunogenicity and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet ii: 467–470, 1988.CrossRefGoogle Scholar
  175. 175.
    Cryz SJ, Levine MM, Kaper JB, et al: Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine in press, 1990.Google Scholar
  176. 176.
    Migasena S, Pitisuttitham P, Prayurahong B, et al: Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun 57: 3261–3264, 1989.PubMedGoogle Scholar
  177. 177.
    Forrest BD, LaBrooy JR, Attridge SR, et al: Immunogenicity of a candidate live oral typhoid/cholera hybrid vaccine in humans. J Infect Dis 159: 145–146, 1989.PubMedCrossRefGoogle Scholar
  178. 178.
    Formal SB, Baron LS, Kopecko DJ, et al: Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galESalmonella typhi Ty21a typhoid vaccine strain. Infect Immun 34: 746–750, 1981.PubMedGoogle Scholar
  179. 179.
    Clements JD, E1-Morshidy S: Construction of a potential live oral bivalent vaccine for typhoid fever and cholem-Escherichia coli-related diarrheas. Infect Immun 46: 564–569, 1984.PubMedGoogle Scholar
  180. 180.
    Tacket CO, Forrest B, Morona R, et al: Safety, immunogenicity and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi. Infect Immun 58: 1620–1627, 1990.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Myron M. Levine
  • Nathaniel F. Pierce

There are no affiliations available

Personalised recommendations